HealthQuill Investigational Drug
Gilead Sciences, Inc., will acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases, for $2 billion, according to a statement. 
Drugs Medical Pharma

Gilead Sciences to acquire US-based Ouro Medicines for up to $2 billion 

Gilead Sciences, Inc., will acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases, for.

Read More
Novartis AG has agreed to buy an investigational oral medicine of Pikavation Therapeutics, a subsidiary of privately-held Synnovation Therapeutics, to treat breast cancer, for a deal worth $3 billion.
Drugs Medical Pharma

Novartis AG to buy experimental oral drug of Pikavation for $3 billion

Novartis AG has agreed to buy an investigational oral medicine of Pikavation Therapeutics, a subsidiary of privately-held Synnovation Therapeutics, to treat breast cancer, for.

Read More
China’s Innovent Biologics and Takeda Pharmaceutical Co. announced a $11.4 billion licensing deal, which will enable the former to speed up the development of its immuno-oncology and antibody-drug conjugate cancer therapies.
Drugs Health Pharma

China’s Innovent, Japan’s Takeda in $11.4 billion deal for cancer therapies

China’s Innovent Biologics and Takeda Pharmaceutical Co. announced a $11.4 billion licensing deal, which will enable the former to speed up the development.

Read More
The US drug regulator halted Rocket Pharmaceuticals Inc.’s investigational gene therapy for Danon disease after a patient died due to an infection, according to a company statement.
Drugs Health Pharma

FDA halts Rocket’s Danon disease mid-stage therapy as patient dies

HQ Team May 28, 2025: The US drug regulator halted Rocket Pharmaceuticals Inc.’s investigational gene therapy for Danon disease after a patient died.

Read More
Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor that may cure chronic pain without using opioids.
Drugs Health Pharma

Eli Lilly to buy SiteOne to grab test inhibitor to treat chronic pain

HQ Team May 28, 2025: Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor.

Read More
GSK Plc will acquire Boston Pharmaceutical’s investigational lead asset, efimosfermin alfa, to treat serious liver diseases, for $2 billion in cash.
Drugs Health Pharma

GSK to buy Boston’s lead drug asset for liver disease for $2 billion in cash

HQ Team May 14, 2025: GSK Plc will acquire Boston Pharmaceutical’s investigational lead asset, efimosfermin alfa, to treat serious liver diseases, for $2.

Read More
Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid tumours, for $2.5 billion in cash.
Drugs Health Medical

Eli Lilly to buy Scorpion Therapeutics’ cancer drug for $2.5 billion

Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid.

Read More
GSK Plc will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.
Drugs Health Medical

GSK to pay Chimagen $300m upfront to develop autoimmune drug 

GSK Plc., will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.

Read More
British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an end-stage trial, according to a joint statement.
Drugs Health Pharma

AstraZeneca-Daiichi Sankyo’s breast cancer drug fails in late-stage trial

British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an.

Read More
Summit Therapeutics Inc.’s investigational drug ivonescimab helps lung cancer patients to cut the risk of progression or death from the disease by 48%, the latest results of the company's trials reveal.
Drugs Health Pharma

Summit’s lung cancer drug reduces risk of disease progression by 48%

Summit Therapeutics Inc.’s investigational drug ivonescimab helps lung cancer patients to cut the risk of progression or death from the disease by 48%,.

Read More